Research

The Division of Infectious Diseases and Tropical Travel Clinic at East Carolina University is involved in clinical and translational research. Research and clinical trial areas include HIV/AIDs, TB, and Hepatitis.

Through new discoveries in the research we strive to improve the quality of care for our patient population. Our research and clinical trials have allowed us to escalate our knowledge and patient care.

Current Projects

Study: Merck. MK-1439-018.
Title: A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects.
Investigator: Paul Cook, MD
Status: This study is no longer enrolling participants.  It is in the final stages.


Study: Gilead GS-US-360-1489.

Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir    Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
Investigator: Paul Cook, MD
Status: Ongoing but no longer enrolling participants.


Study: Gilead GS-US-360-1490
.
Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
Investigator: Paul Cook, MD
Status: Ongoing but no longer enrolling participants.

Study: Gilead GS-US-380-1844 
Title: A Phase 3, Randomized, Double-Blind Study to evaluate the safety and efficacy of switching form a regimen of dolutegravir and ABC/3TC, or a fixed-dose combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 infected subjects who are virologically suppressed.
Investigator: Paul Cook, MD
Status: Ongoing but no longer enrolling participants.

Study: Gilead GS-US-380-1878
Title: 
A Phase 3, Randomized, Open-Label study to evaluate the safety and efficacy of switching from regimens consisting of boosted atazanavir or darunavir plus either emtricitabine/tenofovir or abacavir/lamivudine to GS-9883/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-1 infected adults.
Investigator: Paul Cook, MD
Status: Ongoing but no longer enrolling participants.

Study: Gilead GS-US-1992.
Title: Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment.
Investigator: Paul Cook, MD
Status: Ongoing but in the finishing stages.

Study: Gilead GS-US-380-4030.
Title:
A Phase 3, Randomized, Double-Blind Study to evaluate the safety and efficacy of switching from a regimen of dolutegravir and either emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil fumarate to a fixed dose combination of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 infected subjects who are virologically suppressed.
Investigator: Paul Cook, MD
Status: Ongoing but not enrolling new participants.

Study: TAIMED BIOLOGICS TMB-311.
Title: A Phase 3, multi-center, expanded access study of Ibalizumab plus an optimized background regimen (OBR) in the treatment-experienced patients infected with multi-drug resistant (MDR) HIV-1.
Investigator: Paul Cook, MD
Status: Ongoing but not enrolling new participants